天壇生物(600161.SH)半年度淨利潤升22.21%至2.94億元
格隆匯8月22日丨天壇生物(600161.SH)發佈2019年半年度報告，實現營業收入15.60億元，同比增長27.87%；歸屬於上市公司股東的淨利潤2.94億元，同比增長22.21%；歸屬於上市公司股東的扣除非經常性損益的淨利潤2.93億元，同比增長23.41%；基本每股收益0.28元。
報告期內，公司全面推進漿站質量體系標準化建設，建立質量管理體系文件235份，在營漿站中42家實施了漿站質量體系標準化工作，其餘9家漿站10月底前實施；公司進一步完善漿站高管人員和員工績效考核和薪酬激勵辦法，激發工作積極性，加強獻漿員發展工作，強化血源品牌宣傳，促進了公司採漿量提升；公司持續加大血源拓展力度，下屬武漢血制大同漿站開業、鄖西分站獲採漿許可證。
報告期內，公司實現採集血漿802.55噸，較上年同期淨增加64.22噸，同比增長8.70%。
報告期內，公司較好的完成了生產目標。公司質量管理體系有效運行，有效保證了產品質量，公司下屬五家血制公司產品自檢和批籤發合格率均為100%；公司下屬《單採血漿許可證》到期的10家漿站均按期完成了換證工作。
報告期內，公司積極推動血漿調撥，提升投漿規模；公司加強工藝技術提升和精細化生產管理，人血白蛋白和靜注人免疫球蛋白收率進一步提升。
公司通過共享技術成果、病毒去除滅活技術平台和檢測技術平台，實現研發資源的有效使用，積極助推研發進度，年度重點研發課題進展順利。
成都蓉生的狂犬病人免疫球蛋白已獲得藥品註冊批件，相關血液製品生產車間已通過GMP認證；注射用重組人凝血因子VIII已正式啟動I期臨牀研究；擁有自主知識產權的層析工藝靜丙獲得藥品臨牀試驗通知書。
報告期內，公司獲專利授權6項，包括：人纖維蛋白溶解酶原的凍乾製劑及其製備方法、自動循環加液系統2項發明專利和一種膠塞加註裝置、一種用於血漿蛋白分離的層析柱裝置、基於在實驗中自動傾倒液體的裝置、一種生物實驗用實驗材料高效研磨設備4個實用新型專利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
